

REMARKS

Entry of the claim amendments and additions prior to examination is respectfully requested. Attached hereto is a marked up version of the changes made to the claims. The attached page is entitled "**Version with Markings to Show Changes Made.**"

I. Amendments

Claim 1 has been amended to describe a method for treating a viral disease in a mammal. Basis for this amendment can be found, for example, on page 9, lines 20-24 and page 28, lines 5-31. Claim 1 is also amended to state that the IFN<sub>τ</sub> is administered through oral ingestion, as described, for example on page 7, line 35 to page 8, line 1. Claim 1 further describes that the IFN<sub>τ</sub> is bovine IFN<sub>τ</sub>, as set forth on page 12, line 31.

Claims 2 and 3 are amended to describe that the IFN<sub>τ</sub> is administered at a dosage of greater than about  $1 \times 10^5$  (claim 2) and about  $1 \times 10^6$  (claim 3) units per day. Basis for these amendments can be found on page 31, line 35 to page 32, line 11.

Claims 4 and 5 are amended to recite that the bovine IFN<sub>τ</sub> has an amino acid sequence homology of at least about 80% with ovine IFN<sub>τ</sub> amino acid sequence. Basis for this amendment can be found on page 12, line 31 to page 13, line 4.

Claim 9 is amended to depend from new claim 20, which describes an embodiment where the mammal treated with the IFN<sub>τ</sub> is a domesticated animal. Basis for new claim 20 is on page 29, lines 25-27..

New claim 21 parallels claim 1 for treating a condition associated with cellular proliferation. Basis for treatment of this condition is found, for example, on page 28, line 34 to page 29, line 5 and on page 24, line 35.

Dependent claims 22-28 parallel dependent claims 2-5, 8, 9 and 20, discussed above.

New claim 29 parallels claim 1 for treating an inflammatory disease condition in a mammal, as described, for example, on page 24, line 34.

Dependent claims 30-36 parallel dependent claims 22-28 and 2-5, 8, 9, and 20.

Accordingly, no new matter is added by these amendments.

Respectfully submitted,

Date: 12/21/01

*Judy Mohr*  
Judy M. Mohr  
Registration No. 38,563

**CORRESPONDENCE ADDRESS**

Customer No. 22918  
(650) 838-4300

650-838-4300

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) In a method of treating a viral disease [condition] in a mammal responsive to treatment by ovine interferon-tau (IFN<sub>τ</sub>), an improvement comprising orally administering a therapeutically-effective amount of bovine IFN<sub>τ</sub> through oral ingestion.

2. (Amended) The method of claim 1, wherein IFN<sub>τ</sub> is orally-administered at a dosage of [between] greater than about  $1 \times 10^5$  [and about  $1 \times 10^8$ ] units per day.

3. (Amended) The method of claim [2] 1, wherein IFN<sub>τ</sub> is orally-administered at a dosage of [between] greater than about  $1 \times 10^6$  [and about  $1 \times 10^7$ ] units per day.

4. (Amended) The method of claim 1, wherein the bovine IFN<sub>τ</sub> has an amino acid sequence homology of at least about 80% with an [orally-administered IFN<sub>τ</sub> is] ovine IFN<sub>τ</sub> (OvIFN<sub>τ</sub>) amino acid sequence.

5. (Amended) The method of claim 1, wherein said [OvIFN<sub>τ</sub>] bovine IFN<sub>τ</sub> has [the] a sequence homology of at least about 80% with an ovine IFN<sub>τ</sub> sequence represented as SEQ ID NO:2.

9. (Amended) The method of claim [1] 20, wherein said mammal is a dog.